Ensartinib is a novel and potent domestically developed targeted drug classified as a second-generation ALK inhibitor. It primarily targets patients with advanced non-small cell lung cancer harboring ALK gene fusion mutations, acting by precisely blocking the growth signals of cancer cells. It stands as one of the critical therapeutic choices in this field today.
I. Indications
Ensartinib is utilized across multiple stages of lung cancer treatment, maximizing its efficacy through precision medicine:
First-line Advanced Treatment: For newly diagnosed patients with ALK-positive advanced non-small cell lung cancer, Ensartinib can effectively prolong survival. Studies have shown that its median progression-free survival is significantly superior to that of traditional first-generation targeted therapies.
Postoperative Adjuvant Therapy: For patients with early- to mid-stage ALK-positive lung cancer who have undergone surgical resection, postoperative adjuvant treatment with Ensartinib can effectively reduce the risk of recurrence. It plays a particularly crucial role in preventing brain metastasis, offering a new solution for the postoperative "protection period."
Post-resistance Treatment: It is also suitable for certain patients who have developed resistance or intolerance to first-generation targeted drugs (such as crizotinib).
II. Core Precautions
The use of Ensartinib is subject to strict prerequisites and standards; patients must never self-medicate:
Genetic Testing is Mandatory: Prior to starting treatment, genetic testing must confirm the presence of an ALK gene fusion mutation, otherwise the medication will be ineffective. It is not suitable for lung cancer patients with other mutations such as EGFR or ROS1.
Prescription Only: This is a prescription medication and must be used under the guidance of a physician.
Monitor for Adverse Reactions: Common side effects include rash, abnormal liver function, and constipation, most of which can be managed through dose adjustments or symptomatic treatment. During therapy, regular follow-up checks for routine blood panels, as well as liver and kidney functions, are required, with the entire regimen being evaluated and adjusted by the attending physician.
